OneSource Specialty Pharma Limited has announced that its Board of Directors will convene on January 23, 2026, to review and approve the company's unaudited financial results for the third quarter of fiscal year 2026. The meeting is scheduled in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Meeting Agenda and Financial Review

The board meeting will focus on considering and approving both standalone and consolidated unaudited financial results for the quarter ended December 31, 2025. The company has indicated that other matters may also be discussed during the session, though specific details of additional agenda items have not been disclosed.

Trading Window Restrictions

In accordance with the company's Code of Conduct under the SEBI (Prohibition of Insider Trading) Regulations, 2015, OneSource Specialty Pharma has implemented trading restrictions for designated persons. The trading window closure became effective from January 1, 2026, and will remain in place until 48 hours after the company disseminates its financial results to the public.

Regulatory Compliance

The announcement demonstrates the company's adherence to regulatory requirements under SEBI listing regulations. The formal notification was signed by Trisha A, Company Secretary and Compliance Officer (Membership Number: A47635), and submitted to both major stock exchanges where the company's shares are listed.

The company has requested both BSE Limited and National Stock Exchange of India Ltd to take this information on record, ensuring proper disclosure to market participants and investors ahead of the financial results announcement.

OnSource Specialty Pharma has completed the merger of its Singapore subsidiary Stelis Pte. Limited with OnSource Specialty Pte. Limited. This corporate restructuring initiative consolidates two Singapore-based entities under the pharmaceutical company's international operations.

Corporate Restructuring Details

The merger involves the integration of Stelis Pte. Limited into OnSource Specialty Pte. Limited, both operating as subsidiaries in Singapore. This consolidation represents a strategic organizational move by the pharmaceutical company to streamline its subsidiary structure in the Singapore market.

Strategic Implications

The merger of these Singapore subsidiaries indicates OnSource Specialty Pharma's focus on optimizing its international operational structure. By consolidating these entities, the company aims to enhance operational efficiency and simplify its corporate framework in the Singapore jurisdiction.

This restructuring move reflects the company's ongoing efforts to streamline its global subsidiary network and create a more efficient organizational structure for its international operations.